Cancer Meds from Servier, Taiho, Pfizer’s AA Drug Up for Panel Review on May 29

A key health ministry advisory panel will discuss a batch of medicines for approval on May 29 including Nihon Servier’s antitumor enzyme agent for blood cancer and Taiho Pharmaceutical’s FGFR inhibitor. Nihon Servier’s pegaspargase is one of the three new...read more